PHASE II STUDY ON PACLITAXEL-GEMCITABINE IN RECURRENT OVARIAN CANCER

• Conditions: OVARIAN CANCER RECCURRENCE; MedDRA version: 9.1Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)

• Registration Number: EUCTR2004-004845-17-IT
• Lead Sponsor: POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2007-08-08
• Last Update Posted: 19 March 2012

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: Female
• Target Recruitment: Not specified

Inclusion Criteria

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Not provided

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main Objective: VALUTARE IL TASSO DELLA RISPOSTA DLLA COMBINAZIONE SPERIMENTALE PACLITAXEL-GEMCITABINA <br><br>;Secondary Objective: SOPRAVVIVENZA LIBERA DA PROGRESSIONE SOPRAVVIVENZA GLOBALE QUALITa' DELLA VITA TOSSICITa' <br>;Primary end point(s):